COVID-19: FDA warns of heart risks with Trump-promoted malaria drug | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Thursday
February 09, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
THURSDAY, FEBRUARY 09, 2023
FDA warns of heart risks with Trump-promoted malaria drug

Coronavirus chronicle

UNB/AP
25 April, 2020, 11:05 am
Last modified: 25 April, 2020, 12:07 pm

Related News

  • UNFPA and BRAC host knowledge dissemination event on Covid-19
  • The supply chain crisis opens door to resilience
  • Close to 1,000 migrant children separated by Trump yet to be reunited with parents
  • Hong Kong will give away half a million plane tickets. Here’s who can get them first
  • Haley to challenge Trump for 2024 Republican nomination

FDA warns of heart risks with Trump-promoted malaria drug

The decades-old drugs can cause a number of side effects, including heart rhythm problems, severely low blood pressure and muscle or nerve damage

UNB/AP
25 April, 2020, 11:05 am
Last modified: 25 April, 2020, 12:07 pm
Laura Ng, who has lupus and had to recently call at least five pharmacies before she could find a place to fill her hydroxychloroquine prescription, is photographed in Seattle, Washington, US March 31, 2020/ Reuters
Laura Ng, who has lupus and had to recently call at least five pharmacies before she could find a place to fill her hydroxychloroquine prescription, is photographed in Seattle, Washington, US March 31, 2020/ Reuters

The US Food and Drug Administration on Friday warned doctors against prescribing a malaria drug touted by President Donald Trump for treating the new coronavirus except in hospitals and research studies.

In an alert, regulators flagged reports of sometimes fatal heart side effects  among coronavirus patients taking hydroxychloroquine or the related drug chloroquine. The decades-old drugs, also prescribed for lupus and rheumatoid arthritis, can cause a number of side effects, including heart rhythm problems, severely low blood pressure and muscle or nerve damage.

The warning comes as doctors at a New York hospital published a report that heart rhythm abnormalities developed in most of 84 coronavirus patients treated with hydroxychloroquine and the antibiotic azithromycin, a combo Trump has promoted.

Both drugs are known to sometimes alter the heartbeat in dangerous ways, and their safety or ability to help people with COVID-19 is unknown. A National Institutes of Health experts panel earlier this week recommended against taking that drug combo except in a formal study because of the side effects potential.

Last month, the FDA authorized limited use of the malaria drugs for hospitalized patients with COVID-19 who aren't enrolled in ongoing research. The FDA said the drugs' risks are manageable when patients are carefully screened and monitored by doctors. A number of studies are testing hydroxychloroquine as a treatment or for prevention of COVID-19.

Regulators said they are now investigating dangerous side effects and deaths reported with the malaria drugs to poison control centers and other health authorities.

"It is important that health care providers are aware of the risks of serious and potentially life-threatening heart rhythm problems that can occur with these drugs," the FDA said in a statement. The agency did not specify the number of reports it has received of side effects or deaths.

Calls to US poison control centers about the malaria drugs increased last month to 79, compared to 52 in March 2019, according to Dr. Christopher Hoyte of the Rocky Mountain Poison Center in Denver, Colorado. The problems reported include abnormal heart rhythms, seizures, nausea and vomiting, Hoyte said.

Trump has repeatedly touted hydroxychloroquine during his regular coronavirus briefings, suggesting its skeptics would be proven wrong. He has offered patient testimonials that the drug is a lifesaver.

But a number of early coronavirus studies have suggested problems or no benefit.

In Friday's report in the journal Nature Medicine, doctors at New York University and NYU Langone Health found a significant prolonging of what's called the heart's QT interval two to five days after coronavirus patients were given usual doses of hydroxychloroquine and azithromycin. The drugs can alter the QT interval, or the time it takes the heart to charge between beats. When that time is too long, it can trigger a rhythm problem that can lead to sudden death.

Nine of the 84 patients had severe prolongation of this interval. Four patients died from organ failure but there was no evidence heart problems contributed. Severe disease or other health problems may play a role in whether the heartbeat abnormality develops, the researchers speculated.

The results show how important it is that these drugs only be used in a study where patients are closely tracked, said one independent expert, Dr. Rais Vohra, an emergency medicine specialist at the Fresno branch of the University of California, San Francisco.

"That combination really sets you up for having a problem with the heart," he said. "My colleagues and I are concerned. People are self-medicating and coming down with very predictable side effects on the heart."

Another recent analysis involving 368 patients in US veterans hospitals found no benefit from hydroxychloroquine — and more deaths. The report was not a rigorous test of the drug and results have not yet been reviewed by other scientists but are the largest so far of its use in COVID-19 patients.

Last month, the federal government accepted more than 30 million doses of hydroxychloroquine and chloroquine donated to the strategic national stockpile by drugmakers Sandoz and Bayer. The Federal Emergency Management Agency said Friday it has sent out more than 14 million doses of hydroxychloroquine to state and local health officials. Earlier this month the agency reported that it had sent 19 million doses. The agency didn't explain the discrepancy between the two figures.

Accepting the donation required sign off by both the FDA and the Biomedical Advanced Research and Development Authority, or BARDA, a unit of HHS tasked with procuring treatments to combat bioterrorism and infectious diseases.

Earlier this week, former BARDA director, Rick Bright, said he was demoted from his job leading the agency because he resisted political pressure to allow widespread use of hydroxyc

Top News

Coronavirus Drugs / Donald Trump / hydroxychloroquine / Coronavirus Pandemic / COVID-19 / Coronavirus / Coronavirus treatment / FDA / US Food and Drug Administration (FDA)

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Bangladesh RMG adds more value to products
    Bangladesh RMG adds more value to products
  • Abdulalim Muaini holds onto a rope as rescuers try to pull him out from under the rubble, in the aftermath of a deadly earthquake in Hatay, Turkey, February 8, 2023. REUTERS/Umit Bektas.
    Turkish leader admits 'shortcomings' as quake toll tops 15,000
  • Photo: TBS
    Ganga Vilas: World's longest river cruise anchors in Barishal

MOST VIEWED

  • FILE PHOTO: People wearing face masks commute in a subway station during morning rush hour, following the coronavirus disease ( COVID-19) outbreak, in Beijing, China January 20, 2021. REUTERS/Tingshu Wang
    No new variants in weeks after China ended zero-Covid: Study
  • Tourists ride a tour bus in Hong Kong, China October 25, 2019. REUTERS/Ammar Awad
    Hong Kong will give away half a million plane tickets. Here’s who can get them first
  • People wearing face masks following the coronavirus disease (Covid-19) outbreak are seen at Beijing Daxing International Airport in Beijing, China July 23, 2020. Photo:Reuters
    Pandemic to paradise: Chinese tourists return to Bali after three years
  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs

Related News

  • UNFPA and BRAC host knowledge dissemination event on Covid-19
  • The supply chain crisis opens door to resilience
  • Close to 1,000 migrant children separated by Trump yet to be reunited with parents
  • Hong Kong will give away half a million plane tickets. Here’s who can get them first
  • Haley to challenge Trump for 2024 Republican nomination

Features

Caption1: One of Shaker Ibne Amin’s earliest and most favourite builds which he calls the ‘Soul’. Photo: Saikat Roy

3Monkey Custom Builds: Building custom bicycles in Bangladesh

2h | Wheels
Chinese automobile manufacturers dominate the 2023 Dhaka Motor Fest

Chinese automobile manufacturers dominate the 2023 Dhaka Motor Fest

1h | Wheels
Subhash Chandra Ghosh. Sketch: TBS

No conflicts, no frills: How ABC Ltd remained united for 3 generations and expanded its businesses

3h | Panorama
Illustration: TBS

Planning to study abroad? Explore these four underrated scholarships

1d | Pursuit

More Videos from TBS

Ekushey book fair to see fewer releases this year

Ekushey book fair to see fewer releases this year

Now | TBS Stories
Sirajdikhan's delicious Patkhir is also in demand abroad

Sirajdikhan's delicious Patkhir is also in demand abroad

44m | TBS Stories
LeBron James NBA's all-time highest scorer

LeBron James NBA's all-time highest scorer

44m | TBS SPORTS
Turkaslan's fate is the contrast of Atsu's

Turkaslan's fate is the contrast of Atsu's

49m | TBS SPORTS

Most Read

1
Photo: Courtesy
Panorama

From 'Made in Bangladesh' to 'Designed in Bangladesh'

2
Master plan for futuristic Chattogram city in the making
Districts

Master plan for futuristic Chattogram city in the making

3
Photo: Collected
Crime

Prime Distribution MD Mamun arrested in fraud case

4
Maqsuda Begum made new executive director of Bangladesh Bank
Banking

Maqsuda Begum made new executive director of Bangladesh Bank

5
Photo: Rajib Dhar/TBS
Bangladesh

HSC results to be published Wednesday

6
30% companies see double-digit growth even in hard times
Economy

30% companies see double-digit growth even in hard times

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]